DiaMedica Therapeutics Inc. Other Income and Expense
DiaMedica Therapeutics Inc. (DMAC) reported Other Income and Expense of $1.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-03-30
- DiaMedica Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $483.00K, a 8.52% decline year-over-year.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $419.00K, a 31.98% decline year-over-year.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-06-30 was $314.00K, a 40.30% decline year-over-year.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-03-31 was $443.00K.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for fiscal 2025 was $1.66M, a 26.82% decline from fiscal 2024.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for fiscal 2024 was $2.27M, a 17.52% increase from fiscal 2023.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for fiscal 2023 was $1.93M, a 446.46% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. nonoperating income (expense) for fiscal 2022 was $353.00K, a 330.49% increase from fiscal 2021.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 3 month as first filed | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 6 month as first filed | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $902.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.22M derived: sum of 3 quarters · filed 2026-03-30 | $1.66M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $419.00K 10-Q · filed 2025-11-12 | $733.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.18M 10-Q · filed 2025-11-12 | $1.70M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-06-30 | $314.00K 10-Q · filed 2025-08-12 | $757.00K 10-Q · filed 2025-08-12 | $1.28M derived: sum of 3 quarters · filed 2026-03-30 | $1.90M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2025-03-31 | $443.00K derived: 10-K 12 month − 3 quarters · filed 2026-03-30 | $971.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.59M derived: sum of 3 quarters · filed 2026-03-30 | $2.11M derived: sum of 4 quarters · filed 2026-03-30 | ||
| 2024-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.14M derived: sum of 2 quarters · filed 2026-03-30 | $1.67M derived: sum of 3 quarters · filed 2026-03-30 | $2.27M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $616.00K 10-Q · filed 2025-11-12 | $1.14M derived: sum of 2 quarters · filed 2025-11-12 | $1.74M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $526.00K 10-Q · filed 2025-08-12 | $1.12M 10-Q · filed 2025-08-12 | ||||
| 2023-12-31 | $709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.40M derived: sum of 2 quarters · filed 2025-03-17 | $1.67M derived: sum of 3 quarters · filed 2025-03-17 | $1.93M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $693.00K 10-Q · filed 2023-11-13 | $964.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.22M 10-Q · filed 2023-11-13 | $1.45M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2023-06-30 | $271.00K 10-Q · filed 2023-08-14 | $527.00K 10-Q · filed 2023-08-14 | $756.00K derived: sum of 3 quarters · filed 2024-03-19 | $832.00K derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2023-03-31 | $256.00K 10-Q · filed 2023-05-15 | $485.00K derived: sum of 2 quarters · filed 2024-03-19 | $561.00K derived: sum of 3 quarters · filed 2024-03-19 | $574.00K derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $305.00K derived: sum of 2 quarters · filed 2024-03-19 | $318.00K derived: sum of 3 quarters · filed 2024-03-19 | $353.00K 10-K · filed 2024-03-19 | ||
| 2022-09-30 | $76.00K 10-Q · filed 2023-11-13 | $89.00K derived: sum of 2 quarters · filed 2023-11-13 | $124.00K 10-Q · filed 2023-11-13 | $131.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $13.00K 10-Q · filed 2023-08-14 | $48.00K 10-Q · filed 2023-08-14 | $55.00K derived: sum of 3 quarters · filed 2023-08-14 | $28.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $35.00K 10-Q · filed 2023-05-15 | $42.00K derived: sum of 2 quarters · filed 2023-05-15 | $15.00K derived: sum of 3 quarters · filed 2023-05-15 | $113.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$20.00K derived: sum of 2 quarters · filed 2023-03-28 | $78.00K derived: sum of 3 quarters · filed 2023-03-28 | $82.00K 10-K · filed 2023-03-28 | ||
| 2021-09-30 | -$27.00K 10-Q · filed 2021-11-10 | $71.00K derived: sum of 2 quarters · filed 2021-11-10 | $75.00K 10-Q · filed 2021-11-10 | $150.00K derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2021-06-30 | $98.00K 10-Q · filed 2021-08-11 | $102.00K 10-Q · filed 2021-08-11 | $177.00K derived: sum of 3 quarters · filed 2022-05-04 | $305.00K derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-04 | $79.00K derived: sum of 2 quarters · filed 2022-05-04 | $207.00K derived: sum of 3 quarters · filed 2022-05-04 | $450.00K derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2020-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $203.00K derived: sum of 2 quarters · filed 2022-03-14 | $446.00K derived: sum of 3 quarters · filed 2022-03-14 | $434.00K 10-K · filed 2022-03-14 | ||
| 2020-09-30 | $128.00K 10-Q · filed 2021-11-10 | $371.00K derived: sum of 2 quarters · filed 2021-11-10 | $359.00K 10-Q · filed 2021-11-10 | $651.00K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $243.00K 10-Q · filed 2021-08-11 | -$243.00K 10-Q · filed 2020-08-11 | $231.00K 10-Q · filed 2021-08-11 | -$231.00K 10-Q · filed 2020-08-11 | $523.00K derived: sum of 3 quarters · filed 2021-08-11 | $748.00K derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$12.00K 10-Q · filed 2021-05-05 | $12.00K 10-Q · filed 2020-05-13 | $280.00K derived: sum of 2 quarters · filed 2021-05-05 | $505.00K derived: sum of 3 quarters · filed 2021-05-05 | $225.00K derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | $292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $517.00K derived: sum of 2 quarters · filed 2021-03-10 | $237.00K derived: sum of 3 quarters · filed 2021-03-10 | $975.00K 10-K · filed 2021-03-10 | ||
| 2019-09-30 | $225.00K 10-Q · filed 2020-11-04 | -$55.00K derived: sum of 2 quarters · filed 2020-11-04 | $683.00K 10-Q · filed 2020-11-04 | -$72.00K derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | -$280.00K 10-Q · filed 2020-08-11 | $280.00K 10-Q · filed 2019-08-13 | -$458.00K 10-Q · filed 2020-08-11 | $458.00K 10-Q · filed 2019-08-13 | -$297.00K derived: sum of 3 quarters · filed 2020-08-11 | -$140.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$178.00K 10-Q · filed 2020-05-13 | $178.00K 10-Q · filed 2019-05-13 | -$17.00K derived: sum of 2 quarters · filed 2020-05-13 | $140.00K derived: sum of 3 quarters · filed 2020-05-13 | $271.00K derived: sum of 4 quarters · filed 2020-05-13 | |
| 2018-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $318.00K derived: sum of 2 quarters · filed 2020-03-23 | $449.00K derived: sum of 3 quarters · filed 2020-03-23 | $1.11M 10-K · filed 2020-03-23 | ||
| 2018-09-30 | $157.00K 10-Q · filed 2019-11-13 | $288.00K derived: sum of 2 quarters · filed 2019-11-13 | $946.00K 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | $131.00K 10-Q · filed 2019-08-13 | $789.00K 10-Q · filed 2019-08-13 | ||||
| 2018-03-31 | $657.00K 10-Q · filed 2019-05-13 | |||||
| 2017-12-31 | $259.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |